Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing by Goyanes, A et al.
Accepted Manuscript
Title: Fabrication of controlled-release budesonide tablets via
desktop (FDM) 3D printing
Author: Alvaro Goyanes Hanah Chang Daniel Sedough
Grace B. Hatton Jie Wang Asma Buanz Simon Gaisford
Abdul W. Basit
PII: S0378-5173(15)30308-2
DOI: http://dx.doi.org/doi:10.1016/j.ijpharm.2015.10.039
Reference: IJP 15294
To appear in: International Journal of Pharmaceutics
Received date: 13-8-2015
Revised date: 9-10-2015
Accepted date: 11-10-2015
Please cite this article as: Goyanes, Alvaro, Chang, Hanah, Sedough, Daniel, Hatton,
Grace B., Wang, Jie, Buanz, Asma, Gaisford, Simon, Basit, Abdul W., Fabrication
of controlled-release budesonide tablets via desktop (FDM) 3D printing.International
Journal of Pharmaceutics http://dx.doi.org/10.1016/j.ijpharm.2015.10.039
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
 Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing 
Alvaro Goyanes1, Hanah Chang1, Daniel Sedough1, Grace B. Hatton1, Jie Wang1, Asma 
Buanz1, Simon Gaisford1,2, Abdul W. Basit1,2* a.basit@ucl.ac.uk 
1UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, 
WC1N 1AX, UK 
2FabRx Ltd., 3 Romney Road, Ashford, Kent TN24 0RW, UK 
*Corresponding author. Tel: 020 7753 5865. 
  
 Graphical abstract 
 
  
 Abstract 
 
The aim of this work was to explore the feasibility of using fused deposition modelling 
(FDM) 3D printing (3DP) technology with hot melt extrusion (HME) and fluid bed coating to 
fabricate modified-release budesonide dosage forms. Budesonide was sucessfully loaded 
into polyvinyl alcohol filaments using HME. The filaments were transfomed into capsule-
shaped tablets (caplets) containing 9 mg budesonide using a FDM 3D printer; the caplets 
were then overcoated with a layer of enteric polymer. The final printed formulation was 
tested in a dynamic dissolution bicarbonate buffer system, and two commercial 
budesonide products, Cortiment® (Uceris®) and Entocort®, were also investigated for 
comparison. Budesonide release from the Entocort® formulation was rapid in conditions of 
the upper small intestine while release from the Cortiment® product was more delayed and 
prolonged. In contrast, the new 3D printed caplet formulation started to release in the mid-
small intestine but release then continued in a sustained manner throughout the distal 
intestine and colon. This work has demonstrated the potential of combining FDM 3DP with 
established pharmaceutical processes, including HME and film coating,  to fabricate 
modified release oral dosage forms. 
 
Keywords: Three dimensional printing; modified release; fused filament fabrication; 
budesonide; inflammatory bowel disease; colonic delivery 
  
 1. Introduction 
 
 3-dimensional printing (3DP) technology is being explored as a viable method of 
personalizing medicines at the point of use (Sanderson, 2015). Indeed, 3DP has the 
potential to circumvent formulation challenges associated with myriad drugs, including 
those with narrow therapeutic indices to those whose metabolism is influenced by genetic 
polymorphisms. In addition it facilitates the development of formulations incorporating 
more than one drug (Goyanes et al., 2015e). Such approaches could arguably 
revolutionize clinical management in practice, helping to improve medicine compliance and 
to achieve better therapeutic outcomes. 
 The first equipment used to prepare 3D printed medicines was based on powder 
bed - liquid 3D printing technology (Katstra et al., 2000; Rowe et al., 2000; Yu et al., 2009). 
This technology uses liquids to bind multiple layers of powder to create the desired 
geometry. The limited choice of binder solutions together with the need for high powder 
flow and moisture content control are some of the drawbacks that limit the use of these 3D 
printer types. However, in 2015, the first 3D printed formulation (Spritam®), based on 
powder bed - liquid 3D printing technology (ZipDose®), was approved by the FDA 
(Aprecia_Pharmaceuticals, 2015). Spritam® (levetiracetam) is a fast dissolving tablet 
formulation indicated for the treatment of epileptic seizures. This new product exemplifies 
the opportunities for the use of 3DP technologies to manufacture medicines at industrial 
scale, in addition to personalised therapy at the point of use. 
 
 Fused-deposition modeling (FDM) is a more recent 3DP approach, in which an 
extruded polymer filament is passed through a heated tip. The heat softens the polymer, 
which is then deposited onto a build plate to harden. Layers of the deposited and 
hardened polymer are then built up to create an object in three dimensions. This printing 
method can fabricate hollow objects as well as dosage forms with different drug release 
profiles; the latter is achieved by altering either the infill percentage (Goyanes et al., 2014) 
or surface area/volume ratio of the formulations (Goyanes et al., 2015d). FDM 3DP has 
higher resolution in comparison with previous printing methods, and can, therefore, 
achieve better dosing accuracy that is also easily adjusted by changing parameters in the 
computer software. 
The method of loading polyvinyl alcohol (PVA) polymer filaments with drug prior to printing 
has relied on the need for alcoholic solutions containing the active drug (Goyanes et al., 
2014; Goyanes et al., 2015a; Skowyra et al., 2015), in which filaments are incubated 
overnight, but because of the passive nature of the process, it is only possible to achieve 
low drug loadings. 
  One means of overcoming this problem lies in the use of hot-melt extrusion (HME) 
to obtain drug-loaded PVA filaments (Goyanes et al., 2015d). In the pharmaceutical 
industry, HME is the process by which a rotating screw is used to pump drugs and/or 
excipients at elevated temperatures through a die to generate a product of uniform shape. 
HME is used to incorporate drugs within a matrix at a molecular level to form solid 
solutions/dispersions for drug delivery systems such as pellets and granules (Breitenbach, 
2002; Mehuys et al., 2005; Schilling et al., 2010). Moreover, HME can reduce the number 
of processing steps in dosage form manufacturing, and can be automated as a continuous 
process to give better drug homogeneity. 
 
  In this study, the synthetic corticosteroid budesonide was selected as the model 
drug. Budesonide possesses strong affinity for corticosteroid receptors and features both 
potent topical anti-inflammatory effects (Gionchetti et al., 2014) and low systemic 
bioavailability. It is often used in the treatment of inflammatory bowel disease (IBD) 
(McConnell et al., 2009). Specifically in IBD, modifying budesonide release is a particularly 
desirable goal for the purposes of increasing its duration of action, achieving optimal 
therapeutic levels and reducing associated systemic side effects through targeting specific 
regions of disease activity in the gut. This is achieved mainly by the use of pH-dependent 
coatings applied to tablets or pellets, though there are significant differences in drug 
release and distribution between the commercial formulations (Goyanes et al., 2015b). 
 
 Here, we aimed to create a new budesonide dosage form, combining FDM 3DP 
with HME and fluid bed coating, to achieve appropriate dissolution kinetics. The suitability 
of the HME process to produce budesonide 3D-printable filaments was assessed, along 
with the potential of this method as a valid manufacturing process. The performance of the 
3D printed formulation was evaluated and compared with two commercial pH dependent 
budesonide formulations (Cortiment® 9mg and Entocort® CR 3mg) in a dynamic 
physiological in vitro dissolution model of the human gastrointestinal tract. 
 
2. Materials and Methods 
 
2.1 Materials 
 
Polyvinyl alcohol (PVA), a water-soluble synthetic polymer with a molecular formula of 
(C2H4O)n), was purchased as an extruded commercial filament from Makerbot Inc., USA 
(1.75mm diameter, print temperature 190-220°C). 
 
Budesonide powder of micronized grade was obtained from Sigma Aldrich, UK (molecular 
weight: 430.53g/mol (Figure 1); BCS class II, aqueous solubility 0.0215mg/mL (Yalkowsky 
and He, 2003)). 
 
Eudragit® L100 (pH threshold of 6) was acquired from Evonik, Darmstadt, Germany, 
Triethyl citrate (TEC) and talc were purchased from Sigma Aldrich, UK. Isopropanol 
supplied were of analytical grade. Salts for preparing buffer dissolution were purchased 
from VWR International Ltd., Poole, UK. 
 
Commercial medicines tested in this study were as follows:  
- Cortiment® 9mg, prolonged release tablets (Ferring Pharmaceuticals, UK) 
(commercialized as Uceris® in the US) is tablet formulation with sustained release 
hydrophilic/lipophilic matrix core known as Multi Matrix System (MMX®) and an outer 
coating comprising methacrylic acid – methyl methacrylate copolymer (1:1) (Eudragit® L) 
and methacrylic acid – methyl methacrylate copolymer (1:2) (Eudragit® S) (eMC-
Cortiment, 2015). 
 
- Entocort® CR 3 mg capsules (AstraZeneca UK Limited, UK). Hard gelatine capsules for 
oral administration containing budesonide 3 mg as gastro-resistant prolonged-release 
granules. Granules coated with ethylcellulose and an outer layer of methacrylic acid-
 methyl methacrylate copolymer (1:1) (Eudragit® L); the enteric polymer has a dissolution 
pH threshold of 5.5 (Edsbacker and Andersson, 2004). 
 
2.2 Methods 
 
2.2.1 Preparation of PVA filament loaded with budesonide 
The commercial PVA filament was cut into small cylindrical pellets (~2mm) using a 
Pharma 11 Varicut Pelletizer (Thermo Fisher Scientific, UK). A commercial grinder (Wahl 
ZX789, Wahl store, UK) was used to produce a fine PVA powder with a small particle size 
which was then sifted through a sieve with a mesh size of 1000 µm. Budesonide (2g, 5% 
drug w/w) was manually mixed in together with the PVA powder (38g) using a mortar and 
pestle. The mixture was then extruded using a single-screw extruder (Noztek Pro filament 
extruder, NozteK, UK) at 170 °C through a nozzle with diameter 1.75mm at screw speed of 
15 rpm. The resulting filament was stored in a vacuum desiccator before printing. 
Budesonide loading in the filaments was determined by HPLC analysis. 
 
2.2.2 3D printing of budesonide dosage forms 
Dosage forms were fabricated with the drug-loaded filament using a standard fused-
deposition modelling 3D printer, MakerBot Replicator 2X Desktop (MakerBot Inc., USA). 
The template used to print the dosage form was designed with AutoCAD 2014® (Autodesk 
Inc., USA) and exported as a stereolithography (.stl) file into MakerWare v. 2.4.1 
(MakerBot Inc., USA). The selected geometry of the dosage forms was a rounded hard 
capsule-shaped tablet (caplet) (Figure 2). The dimensions of the caplet were altered such 
that the axis measurements were: X= 12.49mm; Y= 4.64mm; and Z= 4.64mm using the 
scale function. 
 
The printer settings used were as follows: standard resolution with the raft option 
deactivated, support option activated and extrusion temperature of 190 °C; speed while 
extruding: 90mm/s; speed while traveling: 150mm/s; number of shells 2 and layer height of 
0.20mm. The infill percentage was set to 100% to produce high-density caplets. 
 
2.2.3 Coating of 3D printed caplets 
The coating solution was prepared by adding Eudragit® L100 powder (12g) into a mixture 
of isopropanol (97% based on solvent weight) and water while stirring with a magnetic 
stirrer plate. Talc (50% based on polymer weight) was added as an anti-tacking agent in a 
similar manner until a homogenous dispersion was obtained. TEC (10% based on polymer 
weight) was then added to the dispersion. The total solid content of the final dispersion 
was 10% w/w. The caplets were coated using Strea-1 bottom spray fluidized bed coater 
(Aeromatic AG, Bubendorf, Switzerland), to a weight gain of 13%, which was selected to 
provide gastro-resistance. The coating conditions were as follows: Inlet air temperature 
40°C; outlet air temperature 30°C; fan capacity at setting 15 (equivalent to air flow 
150m3/h); atomising pressure of 0.2 bar and a spray rate of 1.0mL/min. After coating, the 
tablets were fluidized further for 15 min in the coater and cured in an oven at 40°C for 24 
hours. 
 
2.2.4 Drug loading of filaments and caplets 
A caplet or a section of drug-loaded strand (approx. 0.3g) was placed in a volumetric flask 
(1L) with a mixture of methanol:water (1:1) under magnetic stirring until complete 
 dissolution (n=2). Samples of the solutions were then filtered through 0.45 µm filters 
(Millipore Ltd, Ireland), and the concentration of drug determined by HPLC (Hewlett 
Packard 1050 Series HPLC system, Agilent Technologies, UK) with a Kinetex 2.6M 
phenylhexyl 100A, 4.6mm x 50mm column (Phenomenex® Cheshire, UK) maintained at 
40°C. The injected volume was 20L.The mobile phase consisted of two components: 
Acetonitrile and water. The former starts at 20% but rises gradually to 60% after 10 
minutes. The flow rate was 1 ml/min and the UV detection was set at 254nm. All 
measurements were made in duplicate. 
 
 
2.2.5 Scanning Electron Microscopy (SEM) 
 Surface and cross-section images of the filament and caplets were taken with an 
SEM (JSM-840A Scanning Microscope, JEOL GmbH, Eching, Germany). All samples for 
SEM testing were coated with carbon (∼30–40 nm) for visualization.Pictures of the tablets 
were taken with a Nikon CoolpixS6150 with the macro option of the menu. 
 
2.2.6 X-ray powder diffraction (XRPD) 
Discs of 23mm diameter x 1mm height made from PVA filament or drug-loaded PVA 
filament were 3D printed and analysed. A sample of pure budesonide was also analysed. 
The X-ray powder diffraction patterns were obtained in a Rigaku MiniFlex 600 (Rigaku, 
USA) using a Cu Kα X-ray source (λ=1.5418Å). The intensity and voltage applied were 15 
mA and 40 kV. The angular range of data acquisition was 3–60° 2θ, with a stepwise size 
of 0.02° at a speed of 5°/min. 
 
2.2.7 Thermal analysis 
 The filament was characterized with Differential Scanning Calorimetry (DSC) and 
Thermogravimetric analysis (TGA). 
 
For DSC measurements, a Q2000 DSC (TA Instruments, LLC, Waters, USA) was used to 
analyse the samples by heating from -30 to 250°C at 10°C/min in pin-holed hermetically 
sealed Tzero aluminium pans. Nitrogen was used as a purge gas at a rate of 50mL/min. 
The DSC was calibrated for temperature and cell constant according to the manufacturer 
instructions. Advantage software and TA Universal Analysis (TA Instruments, LLC, 
Waters, USA) were used to capture and analyse the data, respectively. 
 
For TGA analysis, a Discovery TGA (TA Instruments, LLC, Waters, USA) was used to test 
samples by heating at 10°C/min from room temperature to 300°C in open aluminum pans. 
Nitrogen was used as a purge gas at a rate of 25mL/min. Data collection and analysis 
were performed using Trios software (TA Instruments, LLC, Water, USA). Percentages of 
weight loss (%w/w) were calculated for each sample. 
 
2.2.8 Dynamic dissolution testing conditions 
 Drug dissolution profiles for the coated 3D printed caplets, Cortiment® 9mg and 
Entocort® 3mg were obtained with a USP-II apparatus (Model PTWS, Pharmatest, 
Germany). Three capsules of Entocort® 3mg were tested together in each vessel to match 
the dose of 9mg of the other formulations: 1) the formulations were placed in 750 mL of 
0.1 M HCl for 2 h to simulate gastric residence time, and then 2) transferred into 950 mL of 
 modified Hanks (mHanks) bicarbonate physiological medium for 35 min (pH 5.6 to 7); 3) 
and then in modified Krebs buffer (1000ml) (pH 7 to 7.4 and then to 6.5). The modified 
Hanks buffer based dissolution medium (Liu et al., 2011) (136.9 mM NaCl, 5.37 mM KCl, 
0.812 mM MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4.2H2O, 0.441 mM KH2PO4, 
4.17 mM NaHCO3) forms an in-situ modified Kreb’s buffer (Fadda et al., 2009) by addition 
of 50 mL of pre-Krebs solution (400.7 mM NaHCO3 and 6.9 mM KH2PO4) to each 
dissolution vessel. 
 
The formulations were tested in the small intestinal environment for 3.5 h (pH 5.6 to 7.4), 
followed by pH 6.5 representing the colonic environment. These parameters were selected 
to simulate typical conditions for intestinal transit of pharmaceutical formulations and pH 
values in different segments of the GI tract in fasted individuals. The buffer capacity and 
ionic composition of the physiological bicarbonate buffers also closely match the buffer 
capacities of the intestinal fluids collected from different parts of the gut in humans (Fadda 
et al., 2009; Goyanes et al., 2015b; Goyanes et al., 2015c; Liu et al., 2011). 
 
The medium is primarily a bicarbonate buffer in which bicarbonate (HCO3-) and carbonic 
acid (H2CO3) co-exist in an equilibrium, along with CO2 (aq) resulting from dissociation of 
the carbonic acid. The pH of the buffer system can be decreased by purging CO2 (g) in the 
solution, which promotes the formation of carbonic acid. Similarly, an inert gas (such as 
helium), which removes the dissolved CO2 from the solution, increases the pH of the 
medium. The purging of gases is controlled by an Auto pH SystemTM (Merchant et al., 
2012), which consists of a pH probe connected to a source of carbon dioxide gas (pH-
reducing gas), as well as to a supply of helium (pH-increasing gas), controlled by a control 
unit. The control unit is able to provide a dynamically adjustable pH during testing 
(dynamic conditions) and to maintain a uniform pH value over the otherwise unstable 
bicarbonate buffer pH. 
 
The paddle speed of the USP-II was fixed at 100 rpm, and the tests were conducted at 37 
+/-0.5 °C (n=3). The percentage drug released from the formulations was determined 
using an in-line UV spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, 
UK) at the wavelength of maximum absorbance of budesonide (244nm). Data were 
processed using Icalis software (Icalis Data Systems Ltd, Berkshire, UK), 
 
 
3. Results and Discussion 
 
Budesonide-loaded filaments were successfully prepared using HME (Figure 3). 
Budesonide loading in the filaments was 4.14 ±0.273%, which is considerably higher than 
than loadings achieved through passive diffusion approaches with alcoholic solutions 
(Goyanes et al., 2014; Goyanes et al., 2015a; Skowyra et al., 2015). However, budesonide 
loading was lower than expected (5% w/w), which may be attributed to the adherence of 
powdered drug to the walls of the container on transfer to the hopper of the HME and the 
walls of the barrel during extrusion, and due to irregular extrusion of components. In the 
pharmaceutical industry twin-screw extruders are often used instead of single extruders, 
as the former’s mixing ability is superior to the single-screw extruder. Further parameters 
can also be altered to improve mixing, shear force and pressure within the barrel (Crowley 
et al., 2007; Repka et al., 2007). 
  
TGA analysis (Figure 4) and DSC data (Figure 5) indicate that budesonide is thermally 
stable in the temperature range used in both extruding and printing with a mass loss of 
approximately 0.1% w/w for the raw material and 4% w/w for the drug-loaded filament. 
These data confirm that budesonide is not degraded during HME, indicating that the lower 
than expected loading in the filament is attributable to the feedstock preparation and 
handling. The difference in mass loss seen between the plain PVA and the drug-loaded 
filaments (2 and 4% w/w, respectively) may be caused by differences in water content of 
the filaments. 
 
DSC of budesonide shows a melting temperature higher than 250°C; the DSC data of the 
budesonide-loaded filament showed no evidence of melting (Figure 5). PVA melts at a 
lower temperature than the drug, which may lead to any crystalline drug dissolving in the 
molten polymer. On the other hand, the presence of two diffraction peaks at around 15° in 
the XRPD data (Figure 5) indicates some crystalline phases of the drug exist.. DSC results 
were not conclusive, but the two techniques suggest that the drug may be partially 
crystalline in the formulation. Nevertheless, the glass transition temperature of the PVA 
filament is lower for the drug-loaded filament. This may be because the budesonide is 
acting as a plasticiser interacting with PVA at a molecular level. Budesonide is classified 
as a small chemically manufactured molecule with a large molecular weight:size ratio. Its 
plasticisation effects may be the result of its ability to increase free volume between 
polymer chains (Repka et al., 2007) by interposition and increasing polymer chain motion 
through intermolecular secondary valence forces. This plasticizing effect was also 
demonstrated with prednisolone (Skowyra et al., 2015). 
 
The budesonide-loaded filament was converted into caplets using the FDM 3D printer 
(Figure 6). Budesonide loading in the caplets was 4.10 ±0.296%, which is very similar to 
that of the filament itself, 4.14 ±0.273, indicating that the drug did not degrade during the 
3D printing process; this was anticipated and in accordance with the DSC and TGA 
results. Degradation of the drugs during 3DP was evaluated before, and it is expected if 
the 3DP process takes place at temperatures higher than the degradation temperature of 
the drug (Goyanes et al., 2015a). In order to manufacture caplets with the same 
budesonide content as the Cortiment® product, the dimensions of the caplet were adjusted 
to print a mass equivalent to 9mg of budesonide per caplet (caplet weights of 220mg). 
Skowyra et al., (2015) demonstrated a correlation between the theoretical volume of the 
tablet and its mass on printing using FDM 3DP. In our study, caplets were initially printed 
with commercial PVA filament (drug free) to estimate the dimensions needed to achieve 
the target drug weight. This was then repeated with the budesonide-loaded filament, and 
the scale function was used to produce a smaller or larger dosage form that retained the 
ratio between the dimensions X, Y and Z. This signifies the potential of FDM 3DP to 
manufacture tablets of different geometries and infill percentages in tailoring doses 
accurately and precisely for individual patients where minute increments of dosing may be 
required. 
 
A coat of Eudragit L100 was applied to the 3D printed caplets with the intention of 
producing a gastro-resistant product (Figure 6). The coated printed product was tested 
alongside the two commercial budesonide products in the dynamic in vitro model, which 
simulates intestinal conditions in the GI tract (Goyanes et al., 2015b; Goyanes et al., 
 2015c). Figure 7 depicts the release data for all three formulations. The coated 3D printed 
product is resistant to acidic conditions, and releases after approximately 1 hour in the 
small intestinal segment of the test, which coincides with a pH of pH 7.2, although the 
polymer Eudragit® L100 has a theoretical pH threshold of 6. After coat dissolution, drug 
release from the printed core is sustained and continues in the colonic region. The polymer 
PVA concentration of the commercial filament determines the swelling ratio of PVA 
hydrogels (Gupta et al., 2011) with higher concentrations resulting in a reduced swelling 
ratio. This phenomenon may be responsible for modulating drug release from the drug-
loaded 3DP PVA caplets. Drug release rates from water soluble and swellable polymers 
are governed by the relative contribution of two mechanisms: drug diffusion and polymer 
dissolution (surface erosion) (Reynolds et al., 2002). Drug solubility and the nature of 
excipients are factors that affect which mechanism dominates. Previous studies with 3D 
printed PVA formulations showed that drug release was through an erosion-mediated 
process (Goyanes et al., 2014; Goyanes et al., 2015a). 
 
Entocort® is a commercial medicine that contains budesonide within granules of a matrix of 
ethylcellulose coated with an enteric coated polymer (Eudragit® L) designed to prevent 
dissolution at gastric pH. Budesonide release from the Entocort® formulation is rapid 
(approximately 15 min after gastric emptying), which is in agreement with the results of a 
previous study investigating the dissolution characteristics of oral steroid formulations 
(Goyanes et al., 2015b). In a scintgraphic study, Entocort® was observed to dissolve in the 
duodenum, with the budesonide releasing slowly from the ethylcellulose matrix as it 
passes through the intestine (Edsbacker et al., 2003). In the in vitro model, the Entocort® 
formulation releases more than 90% budesonide at the end of the small intestinal phase of 
the test, with less than 10% of the dose reaching the colon (Goyanes et al., 2015b), and 
with mean maximal budesonide plasma concentrations seen at 3 h following 
administration of Entocort® (Edsbacker et al., 2003). 
 
Cortiment®  (Uceris®) shows a longer lag time and a much slower drug release rate, 
reaching only 50% drug release after 10h. These dissolution results correspond with those 
obtained in a study by Nicholls et al (2013) investigating and comparing the in vivo drug 
release profiles and pharmacokinetics of this product with those of Entocort®. Plasma 
concentration profiles for both Entocort® and Uceris® demonstrated a similar extent (AUC) 
of systemic exposure to budesonide, but the time for first appearance of drug in the 
systemic circulation was significantly delayed for Uceris®. It has been suggested by 
Nicholls that this initial lag period is attributable to more distal gut dissolution and drug 
release from the Uceris formulation than Entocort®. The close similarities between the 
dissolution profiles and the pharmacokinetic results, indicate the predictive value of the 
dynamic dissolution system. 
 
In conclusion, a new modified release 9mg budesonide product was created by combining 
3D printing with HME and film coating. The release characteristics of the new product are 
such that it has potential in the treatment of inflammatory bowel disease. 
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 Figure Captions 
 
Figure.1. Chemical structure of budesonide. 
  
  
Figure 2. Caplet design. 
  
  
Figure 3. SEM images of (A) surface view and (B) cross section of budesonide loaded 
PVA filament after HME. 
  
  
Figure 4. TGA thermal traces for budesonide (raw material), PVA and budesonide-loaded 
PVA filaments. 
  
  
Figure 5. (A) X-ray powder diffractograms of pure budesonide and 3D printed discs of 
PVA and budesonide-PVA (B) DSC thermograms for Budesonide, PVA, budesonide-
loaded PVA filaments and a physical mixture of PVA and the drug. 
  
  
Figure 6. Images of 3DP fabricated caplets (A) from left to right, caplet prior to coating, 
caplet after coating and cross section of coated caplet (scale in cm); (B,C) SEM images of 
internal structure of cross-section of a coated-3D printed caplet. 
  
  
Figure 7. Drug release from Cortiment®, Entocort® and coated 3D printed caplets in 0.1M 
HCl for 2h followed by physiological bicarbonate buffer under dynamic pH conditions (pH 
5.6 to 7.4 and then 6.5) controlled by the Auto pH SystemTM. Red line shows the real-time 
pH values. 
